Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis. Researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust analysed data from 36 Phase I trials run by the organisations' joint Drug Development Unit.

An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease.

A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks and could be more effective than existing treatments, according to a study published in the Lancet.

A compound that mops up debris of damaged cells from the bloodstream may be the first in a new class of drugs designed to address one of medicine's most difficult challenges - stopping the formation of blood clots without triggering equally threatening bleeding.

Patients' non-adherence to prescribed medication costs the U.S. health care system an estimated $290 billion annually and can lead to poor clinical outcomes, increased hospitalizations and higher mortality.

A drug designed to shield the heart from injury during bypass surgery failed to reduce deaths, strokes and other serious events among patients at high risk of complications, according to a large, prospective study lead by researchers at Duke University Medical Center.

Many patients seem to ignore prescription drug warning labels with instructions that are critical for safe and effective use, according to a study by a Kansas State University researcher working with scientists at Michigan State University.